UNIGE document Scientific Article
previous document  unige:96702  next document
add to browser collection
Title

FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion

Authors
Berger, Rolf M F
Haworth, Sheila G
Bonnet, Damien
Dulac, Yves
Fraisse, Alain
Galiè, Nazzareno
Ivy, D Dunbar
Jaïs, Xavier
show hidden authors show all authors [1 - 13]
Published in International Journal of Cardiology. 2016, vol. 202, p. 52-8
Abstract A novel formulation of bosentan was evaluated in children with pulmonary arterial hypertension (PAH) in FUTURE-1, which characterized its pharmacokinetic and clinical profile. The subsequent phase III, open-label, long-term extension study, FUTURE-2, aimed to provide long-term tolerability, safety and exploratory efficacy data.
Keywords Administration, OralAdultBiomarkers, Pharmacological/metabolismDose-Response Relationship, DrugDrug ToleranceEndothelin Receptor Antagonists/administration & dosage/pharmacokineticsFamilial Primary Pulmonary Hypertension/drug therapy/metabolism/mortalityFemaleFollow-Up StudiesGlobal HealthHumansMaleSulfonamides/administration & dosage/pharmacokineticsSurvival Rate/trendsTime FactorsTreatment Outcome
Identifiers
PMID: 26386921
Full text
Article (Published version) (392 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Article (Published version) (123 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group L'hypertension pulmonaire (pédiatrie) (228)
Citation
(ISO format)
BERGER, Rolf M F et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. In: International Journal of Cardiology, 2016, vol. 202, p. 52-8. https://archive-ouverte.unige.ch/unige:96702

13 hits

0 download

Update

Deposited on : 2017-09-14

Export document
Format :
Citation style :